“Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3 3b Clinical Trials”. SKIN The Journal of Cutaneous Medicine 8, no. 4 (July 23, 2024): s404. Accessed April 4, 2025. https://skin.dermsquared.com/skin/article/view/2860.